Marc-Emmanuel Dumas

👩‍🔬 𝐈𝐧 𝐍𝐚𝐭𝐮𝐫𝐞: 𝐍𝐞𝐰 𝐰𝐞𝐢𝐠𝐡𝐭 𝐥𝐨𝐬𝐬 𝐝𝐫𝐮𝐠 𝐭𝐚𝐫𝐠𝐞𝐭 𝐛𝐮𝐫𝐧𝐬 𝐞𝐧𝐞𝐫𝐠𝐲 𝐚𝐧𝐝 𝐥𝐨𝐰𝐞𝐫𝐬 𝐚𝐩𝐩𝐞𝐭𝐢𝐭𝐞 – 𝐰𝐢𝐭𝐡𝐨𝐮𝐭 𝐭𝐡𝐞 𝐧𝐚𝐮𝐬𝐞𝐚 𝐚𝐧𝐝 𝐯𝐨𝐦𝐢𝐭𝐢𝐧𝐠 💊 Millions of people around the world benefit from weight loss drugs based on the incretin hormone GLP-1. These drugs also improve kidney function, reduce the risk of fatal cardiac events, and are linked to protection against neurodegeneration. 🤢 However, many people stop taking the drugs due to common side effects, including nausea and vomiting. Studies also show that incretin-based therapies like Wegovy and Mounjaro are much less effective at lowering weight in people living with both obesity and type 2 diabetes – a group numbering more than 380 million people globally. 🔥 In a study published in @Nature, an international team of scientists describe a powerful new drug candidate that lowers appetite without loss of muscle mass or side effects like nausea and vomiting. And, unlike the current generation of treatments, the drug also increases the body’s energy expenditure – the capacity of the body to burn calories. 💬 "While GLP-1-based therapies have revolutionized patient care for obesity and type 2 diabetes, safely harnessing energy expenditure and controlling appetite without nausea remain two Holy Grails in this field. By addressing these needs, we believe our discovery will propel current approaches to make more tolerable, effective treatments accessible to millions more individuals,” says Associate Professor @Z_GerhartHines Gerhart-Hines from the NNF Center for Basic Metabolic Research (CBMR) at the University of Copenhagen. Read more about the study, by first author @SassFrederike and Tao Ma, below 👇 cbmr.ku.dk/news/2024/new-wei…